GHRP-2 vs GHRP-6

What are GHRP-2 and GHRP-6?

Both are synthetic six-amino-acid peptides that bind the ghrelin receptor (GHS-R1a) and signal the pituitary to release growth hormone. They belong to the growth hormone releasing peptide (GHRP) family and sit in the same functional class as other GH secretagogues studied in humans, such as ipamorelin (Raun et al., 1998). The brief and peer literature confirm both compounds are real GHS-R1a hexapeptides.

Because they work on the ghrelin receptor rather than the GH-releasing hormone (GHRH) receptor, their mechanism differs from GHRH analogs like CJC-1295 (Teichman et al., 2006) and tesamorelin (Falutz et al., 2007). That separation is why the two pathways are sometimes studied together, though this page covers only the GHRP-2 versus GHRP-6 question.

How do GHRP-2 and GHRP-6 differ in mechanism?

Both peptides activate the same receptor (GHS-R1a), but they are reported to differ in selectivity and in how strongly they trigger the appetite side of that receptor. GHS-R1a is the ghrelin receptor, and ghrelin itself drives both GH release and hunger. GHRP-6 is described in the literature as leaning harder into the hunger signal, while GHRP-2 is characterized as a comparatively more selective GH releaser. Human comparative data quantifying this gap is limited, so the difference is best read as directional rather than precise.

Which one releases more growth hormone?

Both are potent GH secretagogues on the same receptor, and published human head-to-head potency data is limited, so no clean winner can be stated from the literature named here. What the broader class literature shows is that ghrelin-receptor agonists reliably raise GH when dosed, and that this effect is short-acting compared with GHRH analogs that sustain GH and IGF-1 over longer windows (Teichman et al., 2006). Anyone comparing GH output should treat single-compound and cross-compound potency claims cautiously, because publicly available controlled comparisons are sparse.

What is the appetite difference between GHRP-2 and GHRP-6?

GHRP-6 is the one associated with the stronger hunger effect in the research literature, and GHRP-2 with a weaker one. This is the difference most often cited when the two are compared. Because both act on the ghrelin receptor, which physiologically drives appetite as well as GH, some hunger response is expected from either; the reported contrast is one of degree. Quantified human appetite-response data separating the two is limited.

What about cortisol and prolactin?

Ghrelin-receptor agonists can raise cortisol and prolactin, and this class trait applies to both peptides, with the magnitude in humans not well quantified in the comparative literature named here. This is why the GHRP family is often discussed alongside hormone monitoring. The safest reading is that both compounds carry a cortisol and prolactin caution, and that neither can be declared "clean" of it on the strength of published comparative trials.

Do they affect blood sugar?

Chronic ghrelin-receptor stimulation can worsen glucose handling, a concern drawn from the wider secretagogue class rather than from GHRP-2 or GHRP-6 trials specifically. In a trial of the oral ghrelin-receptor agonist MK-677, fasting glucose rose and insulin sensitivity fell (Nass et al., 2008). While MK-677 is a different molecule, it targets the same receptor system, so this glucose signal is a reasonable caution to keep in mind when reading about GHRP hexapeptides. Any personal risk assessment belongs with a qualified clinician.

GHRP-2 vs GHRP-6 decision grid

Note: this grid reflects how the compounds are described in the research literature and related class studies. Precise comparative human pharmacokinetics for GHRP-2 versus GHRP-6 are limited, so cells that would require fabricated numbers are left qualitative on purpose.

What does the research report about dosing?

Published, controlled human dosing data comparing GHRP-2 and GHRP-6 directly is limited, so this page does not state dose figures for either. For context on how the broader secretagogue class is studied, ipamorelin was characterized as a selective GH secretagogue in preclinical work (Raun et al., 1998), and GHRH analogs like CJC-1295 have documented human dosing frameworks (Teichman et al., 2006). None of that translates into a personal protocol. Any dose, schedule, or combination decision routes to a qualified clinician, not to a webpage.